Taysha Gene Therapies Stock Price, News & Analysis (NASDAQ:TSHA) $1.79 -0.01 (-0.56%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.74▼$1.8550-Day Range$1.33▼$3.1652-Week Range$0.50▼$3.89Volume2.90 million shsAverage Volume2.02 million shsMarket Capitalization$334.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Taysha Gene Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside229.0% Upside$5.89 Price TargetShort InterestBearish7.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 7 Articles This WeekInsider TradingAcquiring Shares$163,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.69) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector723rd out of 949 stocksBiological Products, Except Diagnostic Industry123rd out of 160 stocks 3.4 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.89, Taysha Gene Therapies has a forecasted upside of 229.0% from its current price of $1.79.Amount of Analyst CoverageTaysha Gene Therapies has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.46% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 42.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 2.4 News and Social Media Coverage News SentimentTaysha Gene Therapies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Taysha Gene Therapies this week, compared to 1 article on an average week.Search Interest8 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $163,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.25% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by InstitutionsOnly 25.91% of the stock of Taysha Gene Therapies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.69) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 89.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Taysha Gene Therapies Stock (NASDAQ:TSHA)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.Read More TSHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Stock News HeadlinesNovember 26, 2023 | morningstar.comTaysha Gene Therapies Inc Ordinary SharesNovember 25, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $5.89 Consensus Target Price from BrokeragesNovember 29, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 24, 2023 | finance.yahoo.comInsider Buying: Taysha Gene Therapies Board Observer Bought US$163k Of SharesNovember 21, 2023 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Paul B. Manning Purchases 100,000 SharesNovember 20, 2023 | americanbankingnews.comCantor Fitzgerald Analysts Reduce Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)November 20, 2023 | americanbankingnews.comChardan Capital Analysts Boost Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)November 19, 2023 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Earnings ForecastsNovember 29, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 17, 2023 | finance.yahoo.comAnalysts Are Upgrading Taysha Gene Therapies, Inc. (NASDAQ:TSHA) After Its Latest ResultsNovember 17, 2023 | markets.businessinsider.comBuy Rating for Taysha Gene Therapies: Promising Efficacy of TSHA-102 in Rett Syndrome Treatment and Strong Financial PositionNovember 15, 2023 | markets.businessinsider.comBuy Rating for Taysha Gene Therapies Amid Significant Patient Improvement and Promising Therapeutic Product EfficacyNovember 14, 2023 | finance.yahoo.comTaysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNovember 14, 2023 | finance.yahoo.comTaysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical ProgressNovember 13, 2023 | benzinga.comA Preview Of Taysha Gene Therapies's EarningsNovember 7, 2023 | finance.yahoo.comTaysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14October 24, 2023 | finance.yahoo.comTaysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressOctober 10, 2023 | finance.yahoo.comTaysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressSeptember 26, 2023 | finance.yahoo.comTaysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett SyndromeSeptember 21, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Taysha Gene Therapies (TSHA), Harmony Biosciences Holdings (HRMY)September 20, 2023 | msn.comDallas-based biotech firm Taysha drops gene therapy following FDA meetingSeptember 19, 2023 | marketwatch.comStocks to Watch: Cambridge Bancorp, Taysha Gene Therapies, Sonder HoldingsSeptember 19, 2023 | markets.businessinsider.comTaysha Discontinues Development Of TSHA-120 In Giant Axonal NeuropathySeptember 19, 2023 | msn.com2 Healthcare Stocks That More Than Tripled Recently. Can They Keep Climbing?September 5, 2023 | finance.yahoo.comTaysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?August 31, 2023 | msn.comTaysha Gene Therapies (TSHA) Price Target Increased by 11.47% to 5.84August 16, 2023 | msn.comDallas biotech snags $150 million lifeline for gene therapy pipelineSee More Headlines Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees65Year Founded2020Price Target and Rating Average Stock Price Target$5.89 High Stock Price Target$10.00 Low Stock Price Target$3.00 Potential Upside/Downside+229.0%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,010,000.00 Net Margins-1,498.57% Pretax Margin-1,494.08% Return on Equity-1,790.06% Return on Assets-90.72% Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual Sales$2.50 million Price / Sales133.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book89.50Miscellaneous Outstanding Shares186,960,000Free Float182,753,000Market Cap$334.66 million OptionableNot Optionable Beta0.13 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 55)CEO & Chairman Comp: $674kDr. Sukumar Nagendran M.D. (Age 56)President, Head of Research & Development and Director Comp: $619.1kMr. Kamran Alam CPA (Age 45)M.B.A., CFO & Corporate Secretary Comp: $703.61kHayleigh CollinsDirector & Head of Corporate CommunicationsMs. Tracy M. Porter SPHRChief People OfficerMr. Frederick Porter Ph.D.Chief of Staff & Technical Operations OfficerMs. Emily McGinnis M.P.H.Chief Patient Advocacy & External Affairs OfficerMr. Sean McAuliffeChief Business OfficerDr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy ProgramBerge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy ProgramMore ExecutivesKey CompetitorsCelcuityNASDAQ:CELCMeiraGTxNASDAQ:MGTXiTeos TherapeuticsNASDAQ:ITOSOculisNASDAQ:OCSUroGen PharmaNASDAQ:URGNView All CompetitorsInsiders & InstitutionsPolar Capital Holdings PlcBought 2,530,000 shares on 11/22/2023Ownership: 1.353%Paul B ManningBought 100,000 shares on 11/17/2023Total: $163,000.00 ($1.63/share)Acuta Capital Partners LLCBought 3,827,926 shares on 11/15/2023Ownership: 2.047%Kynam Capital Management LPBought 3,281,313 shares on 11/15/2023Ownership: 1.755%Adage Capital Partners GP L.L.C.Bought 1,500,000 shares on 11/15/2023Ownership: 0.802%View All Insider TransactionsView All Institutional Transactions TSHA Stock Analysis - Frequently Asked Questions Should I buy or sell Taysha Gene Therapies stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks. What is Taysha Gene Therapies' stock price target for 2024? 11 brokerages have issued 1-year target prices for Taysha Gene Therapies' stock. Their TSHA share price targets range from $3.00 to $10.00. On average, they expect the company's stock price to reach $5.89 in the next twelve months. This suggests a possible upside of 229.0% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts. How have TSHA shares performed in 2023? Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA stock has decreased by 20.8% and is now trading at $1.79. View the best growth stocks for 2023 here. Are investors shorting Taysha Gene Therapies? Taysha Gene Therapies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 13,950,000 shares, an increase of 42.9% from the October 31st total of 9,760,000 shares. Based on an average trading volume of 2,490,000 shares, the days-to-cover ratio is presently 5.6 days. View Taysha Gene Therapies' Short Interest. When is Taysha Gene Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our TSHA earnings forecast. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.02) by $0.33. Taysha Gene Therapies had a negative net margin of 1,498.57% and a negative trailing twelve-month return on equity of 1,790.06%. During the same period last year, the company posted ($1.28) earnings per share. When did Taysha Gene Therapies IPO? (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (13.12%), RA Capital Management L.P. (9.88%), RTW Investments LP (9.04%), Acuta Capital Partners LLC (2.05%), Kynam Capital Management LP (1.76%) and Polar Capital Holdings Plc (1.35%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TSHA) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.